Motavizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Template:Infobox drug/mab source |
Target | RSV glycoprotein F |
Clinical data | |
Trade names | Numax |
Routes of administration | i.v. |
ATC code | |
Pharmacokinetic data | |
Protein binding | None |
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C6476H10014N1706O2008S48 |
Molar mass | Approximately 148 kDa |
(what is this?) (verify) |
WikiDoc Resources for Motavizumab |
Articles |
---|
Most recent articles on Motavizumab Most cited articles on Motavizumab |
Media |
Powerpoint slides on Motavizumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Motavizumab at Clinical Trials.gov Clinical Trials on Motavizumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Motavizumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Motavizumab Discussion groups on Motavizumab Patient Handouts on Motavizumab Directions to Hospitals Treating Motavizumab Risk calculators and risk factors for Motavizumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Motavizumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009[update], it is undergoing Phase II and III clinical trials.[1]
In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[2]
In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[3]
References
- ↑ ClinicalTrials.gov
- ↑ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
- ↑ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.
Template:Monoclonals for infectious disease and toxins
Template:Immune sera and immunoglobulins
Template:AstraZeneca
- Pages with script errors
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Infobox drug tracked parameters
- Drugs that are a monoclonal antibody
- Articles containing potentially dated statements from September 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- AstraZeneca
- Drug
- Monoclonal antibody stubs